198 related articles for article (PubMed ID: 27531416)
1. Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.
Tawar RG; Heydmann L; Bach C; Schüttrumpf J; Chavan S; King BJ; McClure CP; Ball JK; Pessaux P; Habersetzer F; Bartenschlager R; Zeisel MB; Baumert TF
Hepatology; 2016 Nov; 64(5):1495-1506. PubMed ID: 27531416
[TBL] [Abstract][Full Text] [Related]
2. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
Desombere I; Mesalam AA; Urbanowicz RA; Van Houtte F; Verhoye L; Keck ZY; Farhoudi A; Vercauteren K; Weening KE; Baumert TF; Patel AH; Foung SKH; Ball J; Leroux-Roels G; Meuleman P
Antiviral Res; 2017 Dec; 148():53-64. PubMed ID: 29074219
[TBL] [Abstract][Full Text] [Related]
3. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients.
Davis GL; Nelson DR; Terrault N; Pruett TL; Schiano TD; Fletcher CV; Sapan CV; Riser LN; Li Y; Whitley RJ; Gnann JW;
Liver Transpl; 2005 Aug; 11(8):941-9. PubMed ID: 16035063
[TBL] [Abstract][Full Text] [Related]
4. A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
Urbanowicz RA; McClure CP; Brown RJ; Tsoleridis T; Persson MA; Krey T; Irving WL; Ball JK; Tarr AW
J Virol; 2015 Dec; 90(7):3288-301. PubMed ID: 26699643
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.
Wasilewski LN; Ray SC; Bailey JR
J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373
[TBL] [Abstract][Full Text] [Related]
6. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation.
Fafi-Kremer S; Fofana I; Soulier E; Carolla P; Meuleman P; Leroux-Roels G; Patel AH; Cosset FL; Pessaux P; Doffoël M; Wolf P; Stoll-Keller F; Baumert TF
J Exp Med; 2010 Aug; 207(9):2019-31. PubMed ID: 20713596
[TBL] [Abstract][Full Text] [Related]
7. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
Desombere I; Fafi-Kremer S; Van Houtte F; Pessaux P; Farhoudi A; Heydmann L; Verhoye L; Cole S; McKeating JA; Leroux-Roels G; Baumert TF; Patel AH; Meuleman P
Hepatology; 2016 Apr; 63(4):1120-34. PubMed ID: 26710081
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
[TBL] [Abstract][Full Text] [Related]
10. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
[TBL] [Abstract][Full Text] [Related]
11. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients.
Aqel B; Wijarnpreecha K; Pungpapong S; Taner CB; Reddy K; Leise M; Mi L; Dickson RC
J Hepatol; 2021 Apr; 74(4):873-880. PubMed ID: 33188903
[TBL] [Abstract][Full Text] [Related]
12. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
[TBL] [Abstract][Full Text] [Related]
13. Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.
Swann RE; Cowton VM; Robinson MW; Cole SJ; Barclay ST; Mills PR; Thomson EC; McLauchlan J; Patel AH
J Virol; 2016 May; 90(9):4530-4543. PubMed ID: 26912610
[TBL] [Abstract][Full Text] [Related]
14. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
[TBL] [Abstract][Full Text] [Related]
15. Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection.
Wrensch F; Ligat G; Heydmann L; Schuster C; Zeisel MB; Pessaux P; Habersetzer F; King BJ; Tarr AW; Ball JK; Winkler M; Pöhlmann S; Keck ZY; Foung SKH; Baumert TF
Hepatology; 2019 Nov; 70(5):1506-1520. PubMed ID: 31062385
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients.
Eren R; Landstein D; Terkieltaub D; Nussbaum O; Zauberman A; Ben-Porath J; Gopher J; Buchnick R; Kovjazin R; Rosenthal-Galili Z; Aviel S; Ilan E; Shoshany Y; Neville L; Waisman T; Ben-Moshe O; Kischitsky A; Foung SK; Keck ZY; Pappo O; Eid A; Jurim O; Zamir G; Galun E; Dagan S
J Virol; 2006 Mar; 80(6):2654-64. PubMed ID: 16501075
[TBL] [Abstract][Full Text] [Related]
17. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus Recurrence after Liver Transplantation: Real-life Experience in a Mexican Cohort.
Kauffman-Ortega E; Ruiz-Manriquez J; Olivas-Martinez A; Campos-Murguía A; Flores-García NC; Márquez-Guillén E; López-Yáñez S; Sánchez-Ávila F; Toapanta-Yanchapaxi L; Paez-Zayas VM; García-Juárez I
Arch Med Res; 2021 Oct; 52(7):713-718. PubMed ID: 33966917
[TBL] [Abstract][Full Text] [Related]
18. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees.
Morin TJ; Broering TJ; Leav BA; Blair BM; Rowley KJ; Boucher EN; Wang Y; Cheslock PS; Knauber M; Olsen DB; Ludmerer SW; Szabo G; Finberg RW; Purcell RH; Lanford RE; Ambrosino DM; Molrine DC; Babcock GJ
PLoS Pathog; 2012; 8(8):e1002895. PubMed ID: 22952447
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model.
Dent M; Hamorsky K; Vausselin T; Dubuisson J; Miyata Y; Morikawa Y; Matoba N
Cell Mol Gastroenterol Hepatol; 2021; 11(1):185-198. PubMed ID: 32861832
[TBL] [Abstract][Full Text] [Related]
20. Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.
Vercauteren K; Mesalam AA; Leroux-Roels G; Meuleman P
World J Gastroenterol; 2014 Nov; 20(43):15975-91. PubMed ID: 25473151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
